Renalytix (LSE:RENX) Accounts Payable & Accrued Expense : £4.04 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Renalytix Accounts Payable & Accrued Expense?

Renalytix's quarterly accounts payable & accrued expense declined from Sep. 2023 (£2.72 Mil) to Dec. 2023 (£2.30 Mil) but then increased from Dec. 2023 (£2.30 Mil) to Mar. 2024 (£4.04 Mil).

Renalytix's annual accounts payable & accrued expense increased from Jun. 2021 (£1.96 Mil) to Jun. 2022 (£2.04 Mil) and increased from Jun. 2022 (£2.04 Mil) to Jun. 2023 (£2.33 Mil).

Renalytix Accounts Payable & Accrued Expense Historical Data

The historical data trend for Renalytix's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Accounts Payable & Accrued Expense Chart

Renalytix Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.25

2.01

1.96

2.04

2.33

Renalytix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2.64	2.33	2.72	2.30	4.04

Renalytix Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Renalytix (LSE:RENX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (LSE:RENX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

RNLX:USA RTNXF:USA 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix (LSE:RENX) Headlines

From GuruFocus

Causeway International's Top Five Holdings

By Monica Wolfe Monica Wolfe • 08-29-2013

Paul Singer Buys Reed Elesvier

By matsandalex matsandalex • 12-14-2012

Investing in Information

By Vanina Egea Vanina Egea • 03-06-2014

Omnicom Health Group acquires Elsevier's Pharma Communications business in Japan, rebrands as EMC K.K.

By PRNewswire PRNewswire • 03-27-2018